Sudden Bullish Activity for Moleculin Biotech (MBRX); FDA Puts Hold on Some Seattle Genetics’ (SGEN) Drug Trials


Shares of Moleculin Biotech Inc. (Nasdaq:MBRX) soared more than 83% to reach the $3.60 mark in early trade Tuesday, currently changing hands at $2.80, up $0.83 (or +42.25%) with a volume of 2.87M shares traded so far, representing a large increase in activity versus its average volume (3m) of 60,225 shares.

There appears to be no relevant recent news from the preclinical and clinical-stage pharmaceutical company in the street that may explain the sudden bullish activity in the stock.

Moleculin Biotech, which is focused on the development of anti-cancer drug candidates, has 12.05M shares outstanding and MBRX stock 52-week range is from $1.41 to $9.58 per share



Seattle Genetics, Inc. (Nasdaq:SGEN) shares plummeted Tuesday after the biotechnology company said that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on several Phase 1 trials evaluating its vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia.

During the trials in question, six patients presented hepatotoxicity, with four fatal incidents, according to Seattle Genetics.

SGEN stock is trading at $51.81, down $10.05 (or -16.25%) and 3.70M of its shares changed hands so far.

Seattle Genetics, which develops and commercializes targeted therapies for the treatment of cancer, has 141.55M shares outstanding and SGEN stock one-year range is between $26.02 and $75.36 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at